| Product Name | F1+2 ELISA kit (Human) |
|---|---|
| Description | This assay has high sensitivity and excellent specificity for detection of Prothrombin Fragment 1+2 (F1+2). No significant cross-reactivity or interference between Prothrombin Fragment 1+2 (F1+2) and analogues was observed. |
| Method | Sandwich |
| Detection Range | 0.78-50ng/mL |
| Sensitivity | 0.35ng/mL |
| Target | F1+2 |
| Specificity | This assay has high sensitivity and excellent specificity for detection of Prothrombin Fragment 1+2 (F1+2). No significant cross-reactivity or interference between Prothrombin Fragment 1+2 (F1+2) and analogues was observed. |
| Reactivity | Human |
| Sample Types | Plasma |
| Reconstitution | 1.Prepare all reagents, samples and standards; 2.Add 100uL standard or sample to each well.Incubate 2 hours at 37℃; 3.Aspirate and add 100uL prepared Detection Reagent A.Incubate 1 hour at 37℃; 4.Aspirate and wash 3 times; 5.Add 100uL prepared Detection Reagent B.Incubate 30 minutes at 37℃; 6.Aspirate and wash 5 times; 7.Add 90uL Substrate Solution.Incubate 10-20 minutes at 37℃; 8.Add 50uL Stop Solution.Read at 450nm immediately. |
| Uniprot | P00734 |
| Storage | 4°C for 1 month/ -20°C for long-term(within shelf life) |
| Notes | Colormetric |
| References | Disseminated intravascular coagulation or acute coagulopathy of trauma shock early after trauma? An observational study;Changes in thrombin generation, fibrinolysis, platelet and endothelial cell activity, and inflammation following endovascular abdominal aortic aneurysm repair;High levels of soluble VEGF receptor 1 early after trauma are associated with shock, sympathoadrenal activation, glycocalyx degradation and inflammation in severely injured patients: a prospective study;High sCD40L levels early after trauma are associated with enhanced shock, sympathoadrenal activation, tissue and endothelial damage, coagulopathy and mortality;Evaluation of autologous plasma skin test in patients with chronic idiopathic urticaria;Medium-term effect of endovascular and open abdominal aortic aneurysm repair on thrombin generation and fibrinolysis;Markers of Thrombogenesis and Fibrinolysis and Their Relation to Inflammation and Endothelial Activation in Patients with Idiopathic Pulmonary Arterial Hypertension;Effect of endovascular and open abdominal aortic aneurysm repair on thrombin generation and fibrinolysis;Clinical impact of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations among sickle cell disease patients of Central India;Study the association of adiponectin with inflammation and hypercoagulability in case of type 2 diabetic subjects with renal dysfunction;An ex vivo evaluation of blood coagulation and thromboresistance of two extracorporeal circuit coatings with reduced and full heparin dose;Ex vivo simulation of cardiopulmonary bypass with human blood for hemocompatibility testing;Thrombin activatable fibrinolysis inhibitor (TAFI), tissue factor pathway inhibitor (TFPI), and prothrombin fragment 1+2 levels in patients with advanced colorectal cancer ;Perioperative thrombocytopenia predicts poor outcome in patients undergoing transcatheter aortic valve implantation;The causes of thrombocytopenia after transcatheter aortic valve implantation;Elevations of Thrombotic Biomarkers in Hemoglobin H Disease;Enhanced Fibrin-Lysis in Grade-1 Dengue Haemorrhagic Fever;The impact of anti-endothelial cell antibodies (AECAs) on the development of blood vessel damage in patients with systemic lupus erythematosus: the preliminary …; |
| Supplier | Cloud Clone |
PROTOCOLS:
SEA710Hu All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
